Ontology highlight
ABSTRACT:
SUBMITTER: Luque-Cabal M
PROVIDER: S-EPMC4811269 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
Luque-Cabal María M García-Teijido Paula P Fernández-Pérez Yolanda Y Sánchez-Lorenzo Luisa L Palacio-Vázquez Isabel I
Clinical Medicine Insights. Oncology 20160328 Suppl 1
The introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of primary and acquired resistance to trastuzumab treatment remains a significant common challenge. The identification of resistance mechanisms and the incorporation of new drugs that achieve a better blockade of HER family receptors signaling have resulted in improved outcomes. The phosphatidylinositol 3'-kinase/protein kinase B/mammalian target ...[more]